Antibody-structure-based design of pharmacological agents.
The well-studied antigen-combining sites of antibody molecules hold considerable promise as a model system for the design of bioactive peptides. These small, immunoglobulin-derived peptides can be used in the development of alternative treatments for disease and in diagnostic strategies. The general principles derived from the design of small pharmacological agents based on the structural features of antibodies may also be extended to the design of other bioactive peptides.